Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Monitoring vaccine safety using the vaccine safety Datalink: Assessing capacity to integrate data from Immunization Information systems.
Groom HC, Crane B, Naleway AL, Weintraub E, Daley MF, Wain K, Beth Kurilo M, Burganowski R, DeSilva MB, Donahue JG, Glenn SC, Goddard K, Jackson ML, Kharbanda EO, Lewis N, Lou Y, Lugg M, Scotty E, Sy LS, Williams JTB, Irving SA. Groom HC, et al. Among authors: burganowski r. Vaccine. 2022 Jan 31;40(5):752-756. doi: 10.1016/j.vaccine.2021.12.048. Epub 2021 Dec 31. Vaccine. 2022. PMID: 34980508 Free PMC article.
An mRNA Vaccine against SARS-CoV-2 - Preliminary Report.
Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, McCullough MP, Chappell JD, Denison MR, Stevens LJ, Pruijssers AJ, McDermott A, Flach B, Doria-Rose NA, Corbett KS, Morabito KM, O'Dell S, Schmidt SD, Swanson PA 2nd, Padilla M, Mascola JR, Neuzil KM, Bennett H, Sun W, Peters E, Makowski M, Albert J, Cross K, Buchanan W, Pikaart-Tautges R, Ledgerwood JE, Graham BS, Beigel JH; mRNA-1273 Study Group. Jackson LA, et al. N Engl J Med. 2020 Nov 12;383(20):1920-1931. doi: 10.1056/NEJMoa2022483. Epub 2020 Jul 14. N Engl J Med. 2020. PMID: 32663912 Free PMC article. Clinical Trial.
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults.
Anderson EJ, Rouphael NG, Widge AT, Jackson LA, Roberts PC, Makhene M, Chappell JD, Denison MR, Stevens LJ, Pruijssers AJ, McDermott AB, Flach B, Lin BC, Doria-Rose NA, O'Dell S, Schmidt SD, Corbett KS, Swanson PA 2nd, Padilla M, Neuzil KM, Bennett H, Leav B, Makowski M, Albert J, Cross K, Edara VV, Floyd K, Suthar MS, Martinez DR, Baric R, Buchanan W, Luke CJ, Phadke VK, Rostad CA, Ledgerwood JE, Graham BS, Beigel JH; mRNA-1273 Study Group. Anderson EJ, et al. N Engl J Med. 2020 Dec 17;383(25):2427-2438. doi: 10.1056/NEJMoa2028436. Epub 2020 Sep 29. N Engl J Med. 2020. PMID: 32991794 Free PMC article. Clinical Trial.
Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19.
Doria-Rose N, Suthar MS, Makowski M, O'Connell S, McDermott AB, Flach B, Ledgerwood JE, Mascola JR, Graham BS, Lin BC, O'Dell S, Schmidt SD, Widge AT, Edara VV, Anderson EJ, Lai L, Floyd K, Rouphael NG, Zarnitsyna V, Roberts PC, Makhene M, Buchanan W, Luke CJ, Beigel JH, Jackson LA, Neuzil KM, Bennett H, Leav B, Albert J, Kunwar P; mRNA-1273 Study Group. Doria-Rose N, et al. N Engl J Med. 2021 Jun 10;384(23):2259-2261. doi: 10.1056/NEJMc2103916. Epub 2021 Apr 6. N Engl J Med. 2021. PMID: 33822494 Free PMC article. No abstract available.
Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination.
Widge AT, Rouphael NG, Jackson LA, Anderson EJ, Roberts PC, Makhene M, Chappell JD, Denison MR, Stevens LJ, Pruijssers AJ, McDermott AB, Flach B, Lin BC, Doria-Rose NA, O'Dell S, Schmidt SD, Neuzil KM, Bennett H, Leav B, Makowski M, Albert J, Cross K, Edara VV, Floyd K, Suthar MS, Buchanan W, Luke CJ, Ledgerwood JE, Mascola JR, Graham BS, Beigel JH; mRNA-1273 Study Group. Widge AT, et al. N Engl J Med. 2021 Jan 7;384(1):80-82. doi: 10.1056/NEJMc2032195. Epub 2020 Dec 3. N Engl J Med. 2021. PMID: 33270381 Free PMC article. No abstract available.
Baseline representativeness of patients in clinics enrolled in the PRimary care Opioid Use Disorders treatment (PROUD) trial: comparison of trial and non-trial clinics in the same health systems.
Wartko PD, Qiu H, Idu AE, Yu O, McCormack J, Matthews AG, Bobb JF, Saxon AJ, Campbell CI, Liu D, Braciszewski JM, Murphy SM, Burganowski RP, Murphy MT, Horigian VE, Hamilton LK, Lee AK, Boudreau DM, Bradley KA. Wartko PD, et al. Among authors: burganowski rp. BMC Health Serv Res. 2022 Dec 29;22(1):1593. doi: 10.1186/s12913-022-08915-1. BMC Health Serv Res. 2022. PMID: 36581845 Free PMC article.
Nurse Care Management for Opioid Use Disorder Treatment: The PROUD Cluster Randomized Clinical Trial.
Wartko PD, Bobb JF, Boudreau DM, Matthews AG, McCormack J, Lee AK, Qiu H, Yu O, Hyun N, Idu AE, Campbell CI, Saxon AJ, Liu DS, Altschuler A, Samet JH, Labelle CT, Zare-Mehrjerdi M, Stotts AL, Braciszewski JM, Murphy MT, Dryden D, Arnsten JH, Cunningham CO, Horigian VE, Szapocznik J, Glass JE, Caldeiro RM, Phillips RC, Shea M, Bart G, Schwartz RP, McNeely J, Liebschutz JM, Tsui JI, Merrill JO, Lapham GT, Addis M, Bradley KA; PROUD Trial Collaborators; Ghiroli MM, Hamilton LK, Hu Y, LaHue JS, Loree AM, Murphy SM, Northrup TF, Shmueli-Blumberg D, Silva AJ, Weinstein ZM, Wong MT, Burganowski RP. Wartko PD, et al. Among authors: burganowski rp. JAMA Intern Med. 2023 Dec 1;183(12):1343-1354. doi: 10.1001/jamainternmed.2023.5701. JAMA Intern Med. 2023. PMID: 37902748 Free PMC article.
The landscape of use of NCCN-guideline chemotherapy regimens in stage I-IIIA breast cancer in an integrated healthcare delivery system.
Bhimani J, O'Connell K, Persaud S, Blinder V, Burganowski RP, Ergas IJ, Gallagher GB, Griggs JJ, Heon N, Kolevska T, Kotsurovskyy Y, Kroenke CH, Laurent CA, Liu R, Nakata KG, Rivera DR, Roh JM, Tabatabai S, Valice E, Bandera EV, Aiello Bowles EJ, Kushi LH, Kantor ED. Bhimani J, et al. Among authors: burganowski rp. Breast Cancer Res Treat. 2024 Nov;208(2):405-414. doi: 10.1007/s10549-024-07433-4. Epub 2024 Aug 16. Breast Cancer Res Treat. 2024. PMID: 39150586
Patient characteristics associated with delayed time to adjuvant chemotherapy among women treated for stage I-IIIA breast cancer.
Bhimani J, O'Connell K, Persaud S, Blinder V, Burganowski R, Ergas IJ, Foley MJ, Gallagher GB, Griggs JJ, Heon N, Kolevska T, Kotsurovskyy Y, Kroenke CH, Laurent CA, Liu R, Nakata KG, Rivera DR, Roh JM, Tabatabai S, Valice E, Bandera EV, Bowles EJA, Kushi LH, Kantor ED. Bhimani J, et al. Among authors: burganowski r. Int J Cancer. 2024 Nov 1;155(9):1577-1592. doi: 10.1002/ijc.35053. Epub 2024 Jul 6. Int J Cancer. 2024. PMID: 38970396
Offering nurse care management for opioid use disorder in primary care: Impact on emergency and hospital utilization in a cluster-randomized implementation trial.
Bobb JF, Idu AE, Qiu H, Yu O, Boudreau DM, Wartko PD, Matthews AG, McCormack J, Lee AK, Campbell CI, Saxon AJ, Liu DS, Altschuler A, Samet JH, Northrup TF, Braciszewski JM, Murphy MT, Arnsten JH, Cunningham CO, Horigian VE, Szapocznik J, Glass JE, Caldeiro RM, Tsui JI, Burganowski RP, Weinstein ZM, Murphy SM, Hyun N, Bradley KA. Bobb JF, et al. Among authors: burganowski rp. Drug Alcohol Depend. 2024 Aug 1;261:111350. doi: 10.1016/j.drugalcdep.2024.111350. Epub 2024 Jun 10. Drug Alcohol Depend. 2024. PMID: 38875880 Clinical Trial.
15 results